Primmune Therapeutics, Inc. — Form D/A
Primmune Therapeutics, Inc. of San Diego, CA, a company, filed a Form D amendment with the SEC on 2018-01-30. The offering totals $1.5M, of which $1.5M was reported sold. Industry: Other Technology.
Offering
- Filed: 2018-01-30
- Form: D/A
- Accession: 0001683168-18-000244
- Industry: Other Technology
- Exemptions: 06b
- Total offering: $1.5M
- Amount sold: $1.5M
- Investors: 36
- Date of first sale: 2017-10-18
- Revenue range: Decline to Disclose
- SEC file number: 021-298274
Issuer
- Name: Primmune Therapeutics, Inc.
- CIK: 0001721931
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: c/o JLABS San Diego, San Diego, CA, 92121
- Phone: 858-205-2281
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| James R Appleman | Director | Carlsbad, CA |
| Todd J Harris | Director | Carlsbad, CA |
| Paulo S Rangel | Director | Carlsbad, CA |
| James R Appleman | Executive Officer | Carlsbad, CA |
| Paulo S Rangel | Executive Officer | Carlsbad, CA |
| Charles McDermott | Director | San Diego, CA |
| Charles McDermott | Executive Officer | San Diego, CA |
| Scott S Morenstein | Director | San Diego, CA |
| Andrew S Rubinstein | Director | San Diego, CA |
| Amir S Nashat | Director | Cambridge, MA |
Other filings by this issuer (5)
More